Search results

1462 results

Sorted by Date . Sort by Relevance

  1. In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed that further research into the treatment benefit of burosumab in young people aged 13 years and over would relieve some of the clinical uncertainty in an age group covered by the marketing authorisation.

    Recommendation ID HST8/1 Question In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed

  2. The committee also noted that the additional evidence exploring the relationship between radiological measures of bone defects (that is, the Rickets Severity Score and the Radiographic Global Impression of Change) and health-related quality of life would help to address several key uncertainties in the economic analysis.

    Recommendation ID HST8/2 Question The committee also noted that the additional evidence exploring the relationship between radiological

  3. Method of botulinum toxin type A injection in treating focal spasticity:- Is guided botulinum toxin type A injection using electrical localisation (electrostimulation orelectromyography) of muscles more clinically and cost effective than ultrasound-guided injections or clinical positioning for localisation of injections in treating focal spasticity in adults with cerebral palsy?

    Recommendation ID NG119/1 Question Method of botulinum toxin type A injection in treating focal spasticity:- Is guided botulinum toxin

  4. Research is recommended to address uncertainties about the claimed benefits of using Mepilex Border Heel and Sacrum dressings. This research should also explore issues such as:- the incidence of heel and sacrum pressure ulcers in NHS acute care settings- criteria for patient selection to reduce pressure ulcer incidence with Mepilex Border Heel and Sacrum dressings in addition to standard care.NICE will consider reviewing this guidance when substantive new evidence becomes available.

    Recommendation ID MTG40/1 Question Research is recommended to address uncertainties about the claimed benefits of using Mepilex Border

  5. Further research, ideally in the form of randomised controlled trials, on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia should report details of patient selection (including prostate size and the amount of median lobe enlargement), improvement in lower urinary tract symptoms in the short term and long term, re-intervention rates, and outcome measures of sexual function using established methods.

    Recommendation ID IPG641/1 Question Further research, ideally in the form of randomised controlled trials, on the safety and efficacy of

  6. Proposals for further data collection in the Cancer Drugs Fund include:- recurrence-free survival- distant metastases-free survival- overall survival- long-term follow-up of people who received pembrolizumab as an adjuvant treatment- who develop advanced disease and receive pembrolizumab again to treat metastatic disease.

    Recommendation ID TA553/1 Question Proposals for further data collection in the Cancer Drugs Fund include:- recurrence-free survival- distant

  7. Pulmonary rehabilitation during hospital admission:- In people with COPD, does pulmonary rehabilitation during hospital admission for exacerbation and/or in the early recovery period (within 1 month of an exacerbation) improve quality of life and reduce hospitalisations and exacerbations compared with a later (defined as after 1 month)pulmonary rehabilitation programme, and in which groups is it most clinically and cost effective?

    Recommendation ID NG115/1 Question Pulmonary rehabilitation during hospital admission:- In people with COPD, does pulmonary rehabilitation

  8. Multidimensional assessment of outcomes- How can the individual factors associated with COPD prognosis (collected from a range of sources including primary care, imaging and pulmonary rehabilitation results) be combined into a multidimensional analysis that provides accurate and useful information on prognosis?

    Recommendation ID NG115/2 Question Multidimensional assessment of outcomes- How can the individual factors associated with COPD prognosis